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Abstract
Background: Despite the recently reported drop in the overall death rate from cancer, the
estimated survival rate and number of deaths from oral cancer remain virtually unchanged. Early
detection efforts, in combination with strategies for prevention and risk-reduction, have the
potential to dramatically improve clinical outcomes. The identification of non-toxic, effective
treatments, including complementary and alternative therapies, is critical if the survival rate is to be
improved. Epidemiologic studies have suggested a protective effect from certain plant-derived
foods and extracts; however, it has been difficult to isolate and identify the compounds most
responsible for these observations. The primary purpose of this study was to investigate the
response of human oral squamous cell carcinoma (OSCC) to proanthocyanidin (PAC), a plant-
derived compound that may inhibit the progression of several other cancers.
Methods: Using a series of in vitro assays, we sought to quantify the effects of PAC on OSCC,
cervical carcinoma, and non-cancerous cell lines, specifically the effects of PAC on cell proliferation.
Recent data suggest that infection with the human papillomavirus (HPV) may also modulate the
proliferative potential of OSCC; therefore, we also measured the effects of PAC administration on
HPV-transfected OSCC proliferation.
Results: Our results demonstrated that PAC administration was sufficient to significantly suppress
cellular proliferation of OSCC in a dose-dependent manner. In addition, the increased proliferation
of OSCC after transfection with HPV 16 was reduced by the administration of PAC, as was the
proliferation of the cervical cancer and non-cancerous cell lines tested. Our results also provide
preliminary evidence that PAC administration may induce apoptosis in cervical and oral cancer cell
lines, while acting merely to suppress proliferation of the normal cell line control.
Conclusion: These results signify that PAC may be a compelling candidate for testing in both
animal and human models. Furthermore, these data provide adequate justification for elucidating
the divergent mechanisms of PAC-induced proliferation, inhibition, and apoptosis among these and
other cell lines.
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More than 30,000 people are diagnosed with oral cancer
annually in the United States, and due to a poor survival
rate that has remained relatively static, of those who are
diagnosed, approximately 7,500 die of this disease each
year [1]. Many of these patients will subsequently develop
regional tumors, as a result of spreading of the disease to
other organs and lymph nodes [2].
Risk factors are anything that significantly increases the
chance of a person developing a disease, such as oral can-
cer. Scientists now agree that the use of tobacco and alco-
hol, human papillomavirus (HPV) infection, and in the
case of lip cancers, exposure to ultraviolet light, are risk
factors that increase the likelihood of developing oral can-
cers [3]. Thus, many oral cancers are believed to have a
multifactorial etiology in which environmental and
genetic cofactors influence the development and progres-
sion of the disease. Recent evidence suggests that among
these factors, nutrition may play an important role in
retarding the development and progression of oral cancers
[4,5]. A recent meta-analysis examining the association
between fruit and vegetable consumption and the inci-
dence of oral cancer, found a nearly 50% reduction in oral
cancer risk for each additional portion of fruit or vegetable
consumed per day [6].
It is generally accepted that fruit and vegetable intake may
be correlated with a reduction in the incidence of oral can-
cers even among tobacco and alcohol users. The knowl-
edge gained thus far, however, does not provide enough
specific detail upon which to base effective or comprehen-
sive nutrition or dietary intervention recommendations.
More detailed information is needed to identify the active
components of fruits and vegetables, to evaluate dose-
response relationships, and to adjust for potential con-
founders. The stratification of these studies, for example,
has revealed that citrus fruit consumption was associated
with a larger protective effect against oral cancer than
overall fruit consumption, and was greater than green- or
overall vegetable consumption [6].
Based upon these and other observations, a growing inter-
est has been developing in alternative and complementary
medicine to identify botanical and dietary components
for their chemopreventive and chemotherapeutic poten-
tial. One such class of compounds, the proanthocyanidins
(PACs), are polyphenolic compounds that are highly con-
centrated in certain dietary fruits and nuts, such as grapes,
blueberries, cranberries, and almonds, as well as cacao
beans and chocolate [7-10].
PACs belong to a larger class of abundant, plant-derived
compounds, flavonoids, which appear to provide many
beneficial health effects, largely due to their antioxidant
properties. PACs have been shown to protect against oxi-
dative stress and tobacco-induced DNA damage, and to
exhibit selective cytotoxicity against some human cancers,
including breast, lung, prostate, and gastric carcinomas
[11-15]. Extracts from grape peels, grape seeds, and black
raspberries, sources that contain high concentrations of
PAC, have demonstrated selective suppression of tumori-
genic phenotypes in oral cancers, specifically in oral squa-
mous cell carcinomas (OSCC) [16,17].
The possible mechanisms of PACs effects on tumor prolif-
eration are complex and are likely to involve multiple
pathways, which may differ according to the type of can-
cer. For example, PAC derived from grape seed, green tea,
and lowbush blueberry, exhibited broad, anti-prolifera-
tive properties against multiple cell lines, including colon
[18], prostate [14,19-21], breast [22,23], and oral cancers
[24]. Grape seed extract (GSE), a rich source of proan-
thocyanidin, was found to be a potent inhibitor of aro-
matase activity, an enzyme expressed in higher levels in
cancerous than in normal breast tissues [23]. GSE also
induced apoptosis of MCF-7 and MDA-MB-235 breast
cancer cells through modulation of both Bcl-2 and MEK/
ERK signalling pathways [22]. GSE and other flavonoid
extracts were also found to induce apoptosis in colon,
leukemia, and oral cancer cell lines via caspase-3 activa-
tion [15,18,24], and were reported to inhibit ornithine
decarboxylase (ODC), an enzyme involved in epithelial
tumor cell proliferation [13,25,26].
To further evaluate the potential relationship between
oral cancer inhibition and PAC, we sought to identify any
specific or dose-dependent effects that may exist between
the administration of GSE-derived PAC and the prolifera-
tion of oral cancers. In this way, we hope to more defini-
tively characterize the effects of this non-toxic agent for its
chemopreventive or chemotherapeutic value. Quantita-
tive and dose-dependent relationships between PAC
administration and oral cancer proliferation could, there-
fore, be established prior to the identification and elucida-
tion of the pathways involved, and prior to animal and in
vivo studies of this compound.
Based upon the observation that flavonoid-rich extracts,
including PAC, inhibited proliferation of multiple tumor
cell lines, this study examined the potential for PAC to
modulate the proliferative phenotype of OSCC in vitro.
While the aforementioned studies have increased our
understanding of flavonoid- and nutrition-based inhibi-
tion of oral cancer proliferation, none to date have ade-
quately investigated the role of PAC in modulating the
proliferative phenotype of OSCC. This study tested the
hypothesis that PAC modulates, in a dose-dependent
manner, the proliferative phenotype of OSCC in vitro.Page 2 of 12
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eration of the OSCC cell line, CAL 27, in vitro. Further-
more, this inhibition was dose-dependent and was more
pronounced in this oral cancer cell line than in either of
the cervical cancer cell lines that we evaluated, Ca Ski and
GH354. In addition, the maximal growth inhibitory con-
centration (GIMAX) of PAC was sufficient to induce a net
loss of cells (cytotoxic) in CAL 27, but not in either Ca Ski
or GH354 cell lines.
Our previous work established that infection of OSCC
with high-risk HPV 16 strongly promoted the proliferative
potential of OSCC in vitro [27]. Therefore, we further
sought to determine if PAC was capable of modulating
HPV-driven OSCC proliferation in vitro. Our results pro-
vide one of the first demonstrations of HPV modulating
the OSCC proliferative response to PAC. We also found
that PAC inhibited HPV-positive OSCC proliferation and
that the inhibitory concentration of PAC, providing the
maximal proliferation inhibition and cytotoxicity
(GIMAX), was the same for both HPV-positive and HPV-
negative OSCC. These results suggest that PAC may
exhibit selective inhibition of OSCC proliferation and
that PAC administration may be sufficient to inhibit the
increased proliferation of OSCC in the presence of HPV
16.
Standard chemotherapies and radiation treatment, fre-
quently used to treat oral cancer patients, often have harsh
and severe side effects that include tissue damage and
malfunction. The discovery and validation of novel treat-
ments and prevention strategies, lacking these harmful
side effects, is one of our main short-term goals. This
report provides evidence that PAC may provide one possi-
ble complementary or alternative therapy for oral cancer
patients, as a safe, effective, cost-saving, and non-toxic
treatment. We propose that this study provides compel-
ling in vitro data to justify the exploration and elucidation
of the mechanisms of PAC-induced proliferation inhibi-
tion of oral cancers and for testing of PAC in animal mod-
els.
Methods
Materials
Grape seed proanthocyanidin (PAC) extract (Lot
#3717HF7361) was obtained from GNC Preventive
Nutrition® (Pittsburgh, PA). This commercial source of
PAC was extracted from U.S. grown wine grapes, Vitus vin-
ifera. Such commercial sources of grape seed PAC extract
are demonstrated to contain 95% PAC and contain
approximately 80–90% oligomeric PACs, including dim-
ers, trimers, tetramers, and a small amount of monomeric
flavonoids [28,29].
Cell lines and cell culture
Human oral squamous cell carcinoma (OSCC) CAL 27,
human cervical carcinoma (CC) Ca Ski, human cervical
adenocarcinoma (CAC) GH354, and human foreskin
fibroblasts (hFF) Hs27 cell lines were obtained from
American Type Culture Collection (ATCC: Manassas, VA).
CAL 27, GH354, and Hs27 cells were maintained in Dul-
becco's Modified Eagle's Medium (DMEM) with 4.0 mM
L-glutamine adjusted to contain 3.7 g/L sodium bicarbo-
nate, 4.5 g/L glucose, and 110 mg/L sodium pyruvate,
obtained from HyClone (Logan, UT). Ca Ski cells were
maintained in RPMI-1640 medium with 2 mM L-
glutamine, adjusted to contain 1.5 g/L sodium bicarbo-
nate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium
pyruvate, obtained from ATCC. Media was supplemented
with 1% Penicillin (10,000 units/mL)-Streptomycin
(10,000 μg/mL) solution and 10% fetal bovine serum
(FBS), obtained from HyClone, except that GH354 was
supplemented with 20% FBS. Cells were cultured in 75
cm2 BD Falcon tissue-culture treated flasks (Bedford, MA)
at 37°C and 5% CO2 in humidified chambers.
Transfection
CAL 27 cells were seeded in 25 cm2 BD Falcon tissue-cul-
ture treated flasks in appropriate media as described
above and allowed to achieve 70% confluence. Cells were
then transiently transfected by adding 1 μg/mL of the full-
length HPV type 16 virus, cloned into the pBluescript SK-
vector (ATCC #45113). The transfection was performed
using the Stratagene Mammalian Transfection Kit (La
Jolla, CA) according to the manufacturer's recommended
protocol for CaPO4 transfection, and as previously
described [27]. Transfected CAL 27 cells (CAL 27-TF16)
were maintained in the same cell culture conditions as
described above for non-transfected CAL 27 cells. Mock
transfectants of CAL 27 (CAL 27-mTF) were also estab-
lished by performing the transfection protocol, but with-
out using virus.
Microscopy of cell morphology and viability
Cells were visualized with a Zeiss Axiovert 40 inverted
microscope (Gottingen, Germany), and images were cap-
tured at 100× magnification with a Canon PowerShot G6
digital camera (Tokyo, Japan). Digital images were subse-
quently processed using Adobe Photoshop (San Jose, CA)
Image Analysis tools. In brief, several wells of unstained
Ca Ski, GH354, CAL 27, CAL 27-TF16, and Hs27 cells
were photographed at each time point of the proliferation
assays (day 1 – day 4) and at each concentration of PAC
(0 – 100 μg/mL) to visualize any effects on cell morphol-
ogy. In addition, several wells of cells were also fixed at
these time points using 50 μL of 10% buffered formalin
and subsequently stained using crystal violet 1% aqueous
solution (Fisher Scientific: Fair Lawn, NJ) to quantitatively
document cell morphology, percent of cell spreading, andPage 3 of 12
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were stained using Trypan Blue (Sigma: St. Louis, MO)
and live cells were enumerated to determine viability, as
previously described [30,31].
Proliferation
In vitro proliferation assays of CAL 27, CAL 27-mTF, CAL
27-TF16, Ca Ski, GH354, and Hs27 cells were performed
in the appropriate complete media, with and without the
addition of PAC. The total concentrations of PAC used
were between 10 and 100 μg/mL. Cells were plated in
Corning Costar 96-well assay plates (Corning, NY) at a
density of 1.2 × 104 cells per well, maintained at 37°C and
5% CO2 in humidified chambers, and their proliferation
was measured over four days. Cultured cells were fixed
every 24 hrs (day 1 – day 4) using 50 μL of 10% buffered
formalin, and were stained using crystal violet 1% aque-
ous solution. The relative absorbance was measured at
630 nm using a Bio-Tek ELx808 microplate reader
(Winooski, VT). Data were analyzed and graphed using
Microsoft Excel (Redmond, WA). Three separate, inde-
pendent replications of each experiment were performed.
Statistics
The differences between treatments were measured using
a t distribution, α = .05. All samples were analyzed using
two-tailed t tests as departure from normality can make
more of a difference in a one-tailed than in a two-tailed t
test. As long as the sample size is even moderate (>20) for
each group, quite severe departures from normality make
little practical difference in the conclusions reached from
these analyses [32].
RT-PCR
RNA was isolated from 1.5 × 107 cells of CAL 27, CAL 27-
mTF, and CAL 27-TF16, using ABgene Total RNA Isolation
Reagent (Epsom, Surrey, UK) and the procedure recom-
mended by the manufacture. RT-PCR was performed with
the ABgene Reverse-iT One-Step RT-PCR Kit (ReadyMix
Version) and a Mastercycler gradient thermocycler
(Eppendorf: Hamburg, Germany) using the following
primers synthesized by SeqWright (Houston, TX): HPV16
forward primer, ATGTTTCAGGACCCACAGGA; HPV16
reverse primer, CCTCACGTCGCAGTAACTGT. One μg of
template RNA was used for each reaction. The reverse tran-
PAC-induced effects on cell morphology in vitroFigure 1
PAC-induced effects on cell morphology in vitro. Cell lines were cultured in the absence (A-E) or presence (F-J) of PAC 
(50 μg/mL). Ca Ski (A,F) and GH354 (B,G) cervical cancers increased in absolute number and ratio of cell spreading without 
PAC (A,B) but displayed morphological features characteristic of apoptosis under PAC treatment (F,G). CAL 27 (C,H) and 
HPV 16-transfected CAL 27 cells (D,I) also grew in the absence of PAC (C,D), but demonstrated surface blebbing activity and 
morphological changes similar to cervical cells under PAC treatment (H, I). Hs27 normal fibroblast controls (E,J) grew in the 
absence of PAC (E) and less rapidly in the presence of PAC (J), without demonstrable microscopic evidence of apoptotic cellu-
lar features.Page 4 of 12
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turation for 2 min at 94°C. Thirty-five amplification
cycles were run, consisting of 20 sec denaturation at 94°C,
30 sec of annealing at 58°C, and 6.5 min of extension at
72°C. Final extension was run for 5 min at 72°C. Reaction
products were separated by gel electrophoresis using Reli-
ant 4% agarose gels (Cambrex: Rockland, ME). Bands
were visualized by UV illumination of ethidium-bromide-
stained gels and captured using a Kodak Gel Logic 100
Imaging System and 1D Image Analysis Software (East-
man Kodak: Rochester, NY).
DNA isolation
DNA was isolated from 1.5 × 107 CAL 27 and CAL 27-
TF16 cells, cultured with and without PAC, with the
GenomicPrep DNA isolation kit (Amersham Biosciences:
Buckinghamshire, UK), using the procedure recom-
mended by the manufacturer. DNA was separated by gel
electrophoresis using Cambrex Reliant 1% agarose gels
and the bands were visualized by UV illumination of
ethidium-bromide-stained gels and captured using a
Kodak Gel Logic 100 Imaging System and 1D Image Anal-
ysis Software.
Results
Cell morphology
To examine any anti-cancer properties of grape seed-
derived PAC on oral cancers, we began these experiments
with a series of in vitro cell culture experiments designed
to identify morphologic or culture-based effects of PAC,
first on Ca Ski and GH354 cervical cancer cell lines, and
subsequently on CAL 27 and HPV 16-transfected CAL 27
OSCC cell lines, as well as Hs27 normal human foreskin
fibroblast cell line controls (Fig. 1). We utilized PAC
working concentrations of 10, 50, and 100 μg/mL, similar
to the concentrations used in other flavonoid- and GSE-
based assays of oral cancer proliferation [17,24].
Our results demonstrated that both human cervical carci-
noma lines, Ca Ski and GH354 (Fig. 1A, 1B), exhibited
PAC-related changes in cell shape and cell structure at
each concentration of PAC indicative of apoptotic
changes, although these effects were most pronounced at
50 μg/mL (Fig. 1F, 1G). Cells rounded together and were
characterized by substantial cell-surface blebbing, typical
features of epithelial cancers undergoing morphological
alterations associated with apoptosis [5]. Many of these
cervical cancer cells further demonstrated the apparent
rupturing of blisters, generating the appearance of a swol-
len, granular version of the original cells. In addition,
there was a proportional reduction in the number of cells,
the percent of spreading, and cell viability with the
increased dose of PAC (Table 1).
An examination of the OSCC cell line, CAL 27, revealed
PAC-related changes in morphology that paralleled the
changes that were observed for both cervical cancer cell
lines (Fig. 1C, 1H). The overwhelming majority of
attached, spreading cells that were seen in the control
were absent in the PAC experimental wells, with most
PAC-treated cells exhibiting an apoptosis-like morphol-
ogy, including rounded clustering of cells with surface
blebbing and bubbling. In addition, many cells appeared
to be detaching from the growth substrate or were found
as floating cells which could be recovered from the culture
medium. PAC also demonstrated reduction in the
number, spreading, and viability of CAL 27 cells observed
in each assay (Table 1).
Our previous work with CAL 27 demonstrated that trans-
fection with HPV 16 increased the proliferation and
induced the spreading of these cells, even when plated at
low density [27]. In this study, CAL 27-TF16 cells (Fig.
1D) demonstrated a more heterogeneous mixture of cel-
lular morphologies in the presence of PAC (Fig. 1I) than
was observed for non-transfected CAL 27. Some CAL 27-
TF16 cells retained typical spreading, adherent morpholo-
gies, while a smaller proportion of cells exhibited mor-
phologies characteristic of the initial stages of apoptosis.
These early stage-specific features included smaller group-
ings of rounding, clustering cells, cell-surface microspikes,
and blebbing. A less pronounced reduction in cell spread-
ing and cell viability was observed for CAL 27-TF16 (Table
1).
Table 1: PAC-induced effects on cell viability, cell spreading, and 
confluence
- PAC 
[0 μg/ml]
+ PAC 
[50 μg/ml]
% change
Cell viability (%)
Ca Ski 98 10 -88
GH354 96 15 -81
CAL 27 81 10 -71
CAL 27-TF16 95 27 -68
Hs27 99 73 -26
Cell spreading (%)
Ca Ski 99 5 -94
GH354 63 5 -58
CAL 27 85 5 -80
CAL 27-TF16 98 10 -88
Hs27 73 68 -5
Confluence (%)
Ca Ski 88 23 -74
GH354 50 26 -48
CAL 27 45 15 -67
CAL 27-TF16 51 11 -78
Hs27 56 25 -55Page 5 of 12
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PAC-induced effects on cell proliferation in vitroFigure 2
PAC-induced effects on cell proliferation in vitro. 96-well assay plates with media containing 10% fetal bovine serum 
(FBS) in the absence and presence of increasing PAC dosages [0–100 μg/mL] and cells were allowed to proliferate for four 
days. The addition of PAC at low concentration (10 μg/mL) stimulated proliferation of Ca Ski (A), CAL 27 (E) and CAL 27-
TF16 (G) cells, but inhibited proliferation of GH354 (C) and Hs27 (I) cells. Measurement of the relative change in proliferation 
between day 4 and day 1 revealed that the maximal PAC growth inhibition dose (GIMAX) was between 30–60 g/mL for all cell 
lines tested (B,D,F,H,J).
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1E), demonstrated the ability to proliferate and spread in
the presence of PAC at all concentrations (Fig. 1J). In addi-
tion, these cells did not exhibit characteristics of apopto-
sis; however, a reduction in the overall number of cells
was evident at the higher concentration. This apparent
inhibition of cellular proliferation was sustained and
became more pronounced over time, although these
effects on cell viability and cell spreading were less pro-
nounced than for any of the other cell lines tested (Table
1).
Proliferation
Ca Ski (CC) and GH354 (CAC)
To quantitate our observation that the administration of
PAC may inhibit the proliferation of these cancer cell
lines, in addition to the possible induction of apoptosis,
the cervical carcinoma cell lines, Ca Ski and GH354, were
grown in 96-well assay plates and their proliferation was
measured over four days in three separate, independent
experiments. Our results demonstrated that PAC elicited
selective responses in the Ca Ski (HPV 16-containing) and
GH354 (HPV 18-containing) cell lines. Low dose admin-
istration of PAC stimulated Ca Ski proliferation, while
higher doses were inhibitory in a dose-dependent man-
ner. All doses of PAC were inhibitory in GH354 cells,
although the level of inhibition was determined to be
dose dependent.
More specifically, Ca Ski cell proliferation was initially
stimulated by the administration of PAC at the concentra-
tion of 10 μg/mL (+5%), while higher doses, between 20–
100 μg/mL, had an opposite, inhibitory effect on prolifer-
ation (Fig. 2A). To reduce the initial proliferation-stimu-
lating effects of trypsinizing and plating the cells into each
assay, seen between day 0 and day 1 in most assays, we
determined the relative change in proliferation between
day 4 and day 1 (day 4 minus day 1). Our results demon-
strated that the effects of PAC induced only a slight inhi-
bition of cell proliferation between 10–20 μg/mL, but
induced a sharp decrease in proliferation extending over
the range of 30–100 μg/mL with the maximal growth
inhibitory dose (GIMAX) at 50 mg/mL (Fig. 2B).
The effects of PAC administration on GH354 cells pro-
duced slightly different proliferative responses compared
with the effects on Ca Ski cell proliferation (Fig. 2C). For
example, all doses of PAC tested inhibited GH354 prolif-
eration. Although these results suggest that the lowest
dose of PAC (10 μg/mL) had the smallest effect of inhib-
iting proliferation, an analysis of the relative change in
proliferation revealed a more complicated interaction
between PAC effects and GH354 proliferation (Fig. 2D).
These results revealed that all doses of PAC tested were
growth inhibitory; GIMAX was established at 30 μg/mL,
with higher doses exhibiting slightly less robust prolifera-
tion-inhibitory effects.
Hs27 (hFF)
A control cell line, Hs27, human foreskin fibroblasts, was
also tested as described above. Our results demonstrated
that Hs27 cells exhibited dose-dependent responses to
PAC administration (Fig. 2I). GIMAX was determined to be
60 μg/mL, which closely approximated the maximum
inhibitory dosages observed for the other cell lines tested
(Fig. 2J). As with Ca Ski and GH354 cell lines, no dosage
of PAC resulted in a net loss of cells over the course of
these assays.
CAL 27 (OSCC) and CAL 27-TF16 (OSCC)
To test our hypothesis that PAC administration inhibits
proliferation of OSCC, the OSCC cell line, CAL 27, was
assayed and proliferation was measured over four days in
three, separate independent experiments. Our results
demonstrated that PAC induced variable responses, simi-
lar to the effects on Ca Ski cells, in a dose-dependent man-
ner (Fig. 2E). The proliferation of CAL 27 cells was slightly
increased by the lowest concentration of PAC (10 μg/mL),
while increasing doses produced an inhibitory effect on
proliferation over the range of 20–100 μg/mL (Fig. 2F). To
determine the growth inhibitory dose, we analyzed the
relative change in proliferation and found that PAC doses
between 20–40 μg/mL exhibited increasing inhibitory
effects on proliferation, GIMAX was determined to be 50μg/mL, while larger doses, between 60–80 μg/mL, dis-
played ever-diminishing inhibitory effects as the dose was
increased. All PAC doses above 40 μg/mL resulted in a net
loss of cells over the course of the assay.
HPV 16 mediates the proliferation-inhibitory effects of PAC on OSCCFigure 3
HPV 16 mediates the proliferation-inhibitory effects 
of PAC on OSCC. PAC dosage of 50 μg/mL was the GIMAX 
for both CAL 27 and CAL 27-TF16 cells. PAC doses greater 
than 20 μg/mL resulted in a net loss of cells in the CAL 27 
assays, but was modulated by the presence of HPV 16 at dos-
ages above 40 μg/mL in the CAL 27-TF16 assays.Page 7 of 12
(page number not for citation purposes)
BMC Complementary and Alternative Medicine 2007, 7:22 http://www.biomedcentral.com/1472-6882/7/22Our previous studies with OSCC proliferation revealed
that CAL 27 cells proliferated more rapidly after transfec-
tion with HPV 16 [27]. To contextualize our results from
this current study, we assayed HPV 16-transfected CAL 27
cell proliferation under PAC administration over four
days in three, separate independent experiments. Our
results revealed that PAC induced dose-dependent effects,
similar to the responses of CAL 27, with some notable dif-
ferences (Fig. 2G). The proliferation of CAL 27-TF16 cells
was increased by the two lowest concentrations of PAC
(10–20 μg/mL), while further increasing doses produced
inhibitory effects on proliferation within the range of 30–
100 μg/mL. GIMAX was also determined to be 50 μg/mL,
with higher doses exhibiting no greater inhibitory effects
than at GIMAX (Fig. 2H). The maximal inhibitory PAC dose
of 50 μg/mL resulted in a net loss of these cells over the
course of the assay.
To clearly delineate the results of our proliferation assays
for CAL 27 and CAL 27-TF16, cells were plated in the pres-
ence of PAC dosages between 0 and GIMAX (50 μg/mL).
Confirming our previous observations, PAC administra-
tion once again stimulated CAL 27 cells at the lowest con-
centration tested (10 μg/mL), but higher concentrations
inhibited proliferation (Fig. 3). All concentrations above
20 μg/mL resulted in a net loss of cells, with the GIMAX
observed at 50 μg/mL, demonstrating a net loss of more
than 50% of the original number of cells plated at day 0.
PAC administration also stimulated CAL 27-TF16 cells at
low concentrations (10 μg/mL), but higher concentra-
tions induced reduced levels of proliferation. One dispa-
rate result was that PAC administration between 20–30
μg/mL inhibited CAL 27-TF16 cells, unlike the non-trans-
fected CAL 27 cells, without precipitating a net loss of
cells. However, PAC dosages above 40 μg/mL did result in
a net loss of cells with GIMAX determined in this assay to
be 50 μg/mL.
Dose-dependent cell morphology responses
Even though we have described the dose-dependent inhi-
bition of cellular proliferation in response to PAC admin-
istration through in vitro cell culture assays, we wished to
clarify the effects of PAC administration on cell morphol-
ogy at dosages that may provide the most information
about the nature and timing of possible apoptosis events
(Fig. 4). We first examined cell growth in all cell lines in
the absence of PAC for comparison (Fig. 4A–E).
Inhibition of proliferation was induced by treatment of
cells with low concentrations of PAC, sustained over time
Dose-dependent effects of PAC on proliferation and morphologyFigure 4
Dose-dependent effects of PAC on proliferation and morphology. Cells were plated in 96-well assay plates in media 
with FBS. The upper row (A-E) was grown without PAC, the mid-level row (F-J) in the presence of PAC at 20 μg/mL, and the 
lower row (K-O) under PAC administration at 50 μg/mL. All cell lines exhibited a dose-dependent response to PAC adminis-
tration, with higher doses resulting in fewer cells at day 4. Ca Ski (A), CAL 27 (C), CAL 27-TF16 (D) and Hs27 (E) cells were 
reduced in number with PAC at 20 μg/mL (F, H, I, J), unlike GH354 cells (B), which experienced a reduction in proliferation, 
and morphological changes indicative of apoptosis (G). Cellular proliferation was reduced by PAC in all cell lines (K-O) at 50 
μg/mL; all cell lines exhibited altered morphology, except Hs27 (O) cells which appeared normal, although fewer in number.Page 8 of 12
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Ca Ski and GH354, we observed that cell number was
reduced in Ca Ski cultures (Fig. 4F), but that both mor-
phology and cell number were altered in GH354 cells
(Fig. 4G) at low PAC concentration (20 μg/mL). The same
concentration of PAC reduced the overall number of Hs27
cells, without inducing demonstrable changes in cell mor-
phology (Fig. 4J). The OSCC cell lines, CAL 27 (Fig. 4H)
and CAL 27-TF16 (Fig. 4I), also exhibited reduced prolif-
eration in response to this PAC concentration, but exhib-
ited no specific evidence of apoptotic events.
Higher concentrations of PAC, on the other hand, elicited
different responses in cell morphology and appearance.
Cell clustering and rounding was induced in all cancer cell
lines (K-N) with PAC (50 μg/mL). Possible evidence of
apoptosis at this concentration was first observed in all
cell lines, except Hs27 (Fig. 4O), between 18 and 24
hours, and was observed as a relatively slow event that
resulted in a rounding of cells together followed by
intense surface blebbing. Surface blebbing continued
from day 1 to day 4 until more active blistering and lytic
events resulted in the net loss of cells in each assay.
The cervical carcinoma cell line, Ca Ski (Fig. 4F), and
HPV16-transfected OSCC cell line, CAL 27-TF16 (Fig. 4I),
were more resistant to lysis and cell death at the lower
PAC concentration (20 μg/mL) and appeared to be
rounded and blebbing at day 4, while the majority of
GH354 cells (Fig. 4G) and non-transfected CAL 27 cells
(Fig. 4H) may have already undergone these transforma-
tions. The higher PAC concentration (50 μg/mL approxi-
mating GIMAX) further reduced absolute cell number and
induced these morphologic changes in all cell lines (Fig.
4K–N), except Hs27 cells which exhibited no evidence
suggesting apoptotic changes (Fig. 4O).
Nucleic acid analysis
To confirm that the CAL 27 cells used in this study did not
harbor HPV 16 prior to transfection, we performed RT-
PCR on total RNA isolated from cultured CAL 27 cells
used for these experiments and oligonucleotide primers
specific for the HPV 16 strain (Fig. 5A). Our results dem-
onstrated that neither CAL 27 cells (Lane 1) nor CAL 27
mock-transfected cells (Lane 2) expressed HPV 16 mRNA
prior to transfection. After completing transient transfec-
tion of CAL 27 with HPV 16, our results confirmed that
CAL 27-TF16 cells expressed HPV 16-specific mRNA (Lane
3). HPV 16-specific primers were tested using PCR and the
HPV 16 DNA template (Lane 4) to confirm the band size
and specificity of the primers to the template.
The administration of PAC had multiple effects, including
a dose-dependent reduction in cellular proliferation and
changes in cellular morphology among cancer cell lines.
This study also assessed total DNA isolated from CAL 27
and CAL 27-TF16 cells in the absence and presence of PAC
at 50 μg/mL (Fig. 5B), revealing that PAC administration
induced some alteration and fragmentation of total DNA,
resulting in a more diffuse and less compact banding pat-
tern. In addition, PAC administration reduced the overall
molecular weight of the chromosomal DNA extracted,
which may represent one stage in the process of DNA frag-
mentation, characteristic of cells undergoing necrosis or
apoptosis.
Discussion
Proanthocyanidins are part of a larger group of com-
pounds that have been demonstrated to have anti-prolif-
erative and anti-tumor effects [13,26,33]. PAC can be
isolated from multiple sources and the therapeutic bene-
fits of PAC may be determined, in part, by the fruit or veg-
etable from which it is derived [34]. GSE and other fruit-
derived flavonoid extracts have demonstrated robust anti-
proliferative effects on other oral and epithelial cancers
[17,24,35,36].
Although other studies have demonstrated that particular
fractions of GSE or raspberry extracts may be cytotoxic
against oral tumor cell lines, none have yet examined PAC
specifically to analyze its effects on oral cancer prolifera-
tion. Through this study, we have demonstrated that PAC
exhibited dose-dependent inhibitory and cytotoxic effects
Total RNA and DNA analysis of CAL 27 cellsFigure 5
Total RNA and DNA analysis of CAL 27 cells. RT-PCR 
performed on total RNA extracted from OSCC, CAL 27, 
revealed that CAL 27 did not express HPV 16-specific 
mRNA (A: Lane 1). Mock transfectants (A: Lane 2) also did 
not express HPV. HPV 16-transfected cells (A: Lane 3) 
expressed HPV 16; specific primers were tested using PCR 
and the full-length HPV 16-DNA template (A: Lane 4). Total 
DNA isolated from CAL 27 cells (B: Lane 1) and CAL 27-
TF16 cells (B: Lane 3) demonstrated DNA alterations follow-
ing PAC treatment (50 μg/mL), including a more diffuse 
banding pattern and lower molecular weight, possibly indicat-
ing the onset of DNA fragmentation among the treated cells 
(B: Lane 2, 4).Page 9 of 12
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tive and intensely specific for OSCC. In addition, HPV,
now believed to initiate oral cancers among non-smokers,
and to modulate OSCC proliferation and progression
among smokers, was modulated and reduced, in a dose-
dependent manner, by the administration of PAC.
A closer examination of PAC administration among these
various cell lines revealed that the effects of PAC were less
intense and more gradual in the foreskin and cervical can-
cer cell lines, Hs27 and Ca Ski, respectively. In contrast, at
even the lowest dosages, PAC substantially inhibited the
proliferation of both the cervical cancer cell line, GH354,
and the OSCC cell line, CAL 27. Furthermore, the level of
inhibition was dissimilar between these two cancers –
only limiting proliferation of the cervical cell line,
GH354, but resulting in a net loss of cells in the oral can-
cer line, CAL 27. This level of cytotoxicity may represent a
selective effect which suggests that OSCC may be rendered
more susceptible to this treatment.
Although we found that PAC exhibited a general inhibi-
tory effect on all cell lines tested, a morphological change
was observed after PAC administration in both the cervi-
cal and oral cancer cell lines that suggested the possible
induction of apoptosis. Images obtained from live cell
cultures under PAC administration demonstrated that
many of the cells were clustering, rounding, and blebbing
– morphologic changes that are often suggestive of apop-
tosis. However, once the cells were fixed and stained to
quantify these effects on proliferation, only Ca Ski cells
and non-cancerous controls Hs27 were sufficiently
adhered to remain in the assay plates at the GIMAX concen-
tration of PAC. One possible reason for this phenomenon
may be the degree of progression toward apoptosis or cell
death; the more susceptible cell lines, such as GH354,
CAL 27, and CAL 27-TF16, could be further along the
apoptotic pathway and therefore less capable of adhering
and more likely to be removed by mechanical forces dur-
ing the fixation and staining process. The DNA analysis
revealed fragmentation, but no banding patterns indica-
tive of internucleosomal cleavage, suggesting further
experimentation will be necessary to delineate the path-
ways and mechanisms associated with these changes.
Aside from demonstrating that PAC may exhibit differen-
tial effects among different cancers, we found convincing
evidence that HPV may modulate, and in turn be modu-
lated by, the effects of PAC with respect to the OSCC pro-
liferative response. Our previous research found that HPV
16 strongly induced OSCC proliferation and our findings
here indicate that HPV 16 also influenced OSCC response
under PAC administration. The introduction of HPV 16
into these cells not only increased their relative levels of
proliferation, but also mediated their response to PAC,
with lower dosages actually stimulating proliferation of
CAL 27-TF16 cells. Interestingly, the GIMAX was deter-
mined to be invariable for both transfected and non-
transfected cells, suggesting that despite this modulating
effect, the HPV 16-specific effect was not sufficient to alter
OSCC proliferation in response to incremental increases
of PAC administration at or beyond GIMAX.
One critical goal of cancer treatment is to find chemopre-
ventive and therapeutic agents that selectively target can-
cer cells without detrimental effects to healthy cells and
tissues. Although many chemotherapeutic agents are cur-
rently being used in the treatment of oral cancers, such as
cisplatin (CDDP) and 5-fluorouracil (5-FU), it is known
that most tumors may be more or less resistant to these
drug therapies because they are not dependent on a single
receptor or signal transduction pathway for growth and
progression [5]. Thus, compounds or combinations of
compounds that may activate multiple apoptotic path-
ways, such as PACs, may provide new and more effective
treatment regimens for patients with oral cancer.
Recent studies have determined that PACs can be admin-
istered orally as a dietary supplement and are subse-
quently bioavailable, in both serum and tissues at μg/mL
concentrations, without any significant toxicity, implying
that PACs may represent one class of promising candi-
dates for use as an adjuvant therapeutic agent in patients
receiving chemotherapy for oral cancer [37,38]. The sup-
porting evidence that GSE and other flavonoid extracts are
effective as adjuvants and treatments for breast, colon,
and prostate cancer, combined with the results of this
study, demonstrate that PAC may act even more selec-
tively on OSCC than other cell lines. This suggests the pos-
sibility that PACs may act synergistically to induce
selective inhibition and apoptosis of oral cancers in vivo.
Conclusion
PAC-containing commercial products, such as ActiVin®,
OptiBerry®, Grape Seed Proanthocyanidin Extract, and
others, have been verified as well-tolerated and non-toxic
[33,34,39]. However, due to incomplete information
regarding alternative and combination therapies, we
advocate here for systematic animal, and subsequently
human chemoprevention trials, to confirm that PAC may
suppress tumor proliferation or induce tumor apoptosis,
without eliciting deleterious effects on viability and
growth of normal tissue. This study provides convincing
evidence that PAC administration is sufficient to reduce
OSCC proliferation in vitro and that it may also effectively
modulate the proliferation-enhancing effects of concomi-
tant HPV infection. Consequently, if these effects can be
substantiated, it will then become vital to decipher which
of the signalling pathways PAC may influence in OSCC,
including the possible inhibition of MAPK (mitogen acti-Page 10 of 12
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EGFR (epidermal growth factor receptor), or caspase-
dependent pathways.
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